Maintenance Chemo Improves Pediatric RMS.
Findings from a 10-year clinical trial show improved survival rates among children with high-risk rhabdomyosarcoma who receive low-dose maintenance chemotherapy following standard treatment. The results have established a new standard of care for this disease in the EU.